Unlike other forms of treatment, CAR-T therapy is specifically developed for each individual patient and involves reprogramming the patient’s own immune system cells which are then used to target their cancer.
NHS England has announced that tisagenlecleucel is to be made available on the NHS for children and adults up to age 25 years for B cell acute lymphoblastic leukaemia.